Shenogen Pharma Group and Chemizon Inc. Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
2/10/2010 11:12:45 AM
BEIJING & SEOUL, South Korea--(BUSINESS WIRE)--Shenogen Pharma Group and Chemizon, a division of Optomagic Co. Ltd. (KOSDAQ: 0101070) today announced a drug discovery collaboration agreement to create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
comments powered by